Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. Mai 2026 08:00 ET | Quelle: Medidata Solutions, Inc.

Medidata’s Next-Gen AI Imaging Solution Delivers Unprecedented Speed and Precision for Clinical Trials

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions, today unveiled its enhanced, AI-powered imaging solution, within the...
28. Mai 2026 04:00 ET | Quelle: Anaveon

Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Anaveon reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 & actively seeks Partners for its Legacy Oncology Portfolio.
11. Mai 2026 04:00 ET | Quelle: Anaveon

Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Anaveon announces presentation of positive ANV600 Clinical Data at ASCO 2026 and actively seeks partners for its legacy Oncology Portfolio.
07. Mai 2026 07:00 ET | Quelle: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

Entrada Therapeutics announces positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study.
06. Mai 2026 16:30 ET | Quelle: Entrada Therapeutics, Inc.

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

Entrada Therapeutics will announce topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026.
22. April 2026 07:25 ET | Quelle: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with...
04. März 2026 08:00 ET | Quelle: Medidata Solutions, Inc.

Medidata and CRIO Empower Over 2,500 Global Research Sites with Seamless Integration to Accelerate Clinical Trials

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has announced a partnership with...
02. März 2026 04:30 ET | Quelle: SNS Insider pvt ltd

Healthcare Interoperability Solutions Market Size to Reach USD 15.13 Billion by 2035; Growth is Driven by the Increasing Adoption of Electronic Health Records Globally

Healthcare Interoperability Solutions Market to reach USD 15.13 Bn by 2035, driven by EHR adoption, federal mandates, & demand for seamless data exchange.
25. Februar 2026 11:05 ET | Quelle: Longeveron

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Results of Phase 2b clinical trial demonstrating stem cell therapy improved condition of patients with aging frailty published in Cell Stem Cell journal.
25. Februar 2026 09:45 ET | Quelle: ALTRUST Services

ALTRUST and ALTRUE Partner to Rebuild Healthcare Tech from the Ground Up

Clearwater, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Step into any clinic or hospital today and you’ll see it. Providers toggling between five platforms. Administrators chasing reports across systems...

Nächste Seite